BioNTech, Bristol Myers' Pumitamig Shows 36.7% Response Rate In Phase 2 NSCLC Trial

BioNTech and Bristol Myers Squibb announced the first data from the Phase 2 ROSETTA Lung-107 trial of pumitamig plus docetaxel in patients with metastatic NSCLC whose disease progressed on or after first-line treatment. The provided article excerpt ends before reporting any efficacy or safety results, so the clinical findings and their implications cannot be assessed.